Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM Scientist Dr.Michael.Gray speaking today: CHI I-O Conference/SanFran

Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & Immuno-Oncology”, SanFran
“Models & Approaches to Bring Combination Therapies to the Clinic”
Part of the 24th Intl. Molecular Medicine Tri-Conference
http://www.triconference.com/Pre-Clinical-Oncology-Models
CHI = Cambridge Healthtech Institute http://www.healthtech.com
Track: TUMOR MODELS FOR CANCER IMMUNOTHERAPY
2-21-17 11:15-11:45am: Michael Gray (Sr.Res.Sci.), Peregrine Pharmaceuticals - “Case Study: Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
SUMMARY: Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of checkpoint antibodies in preclinical tumor models.
- - - - -
DR. MICHAEL GRAY (Principal Scientist, Peregrine 12-2014) - Prev: Quanticel Pharm, OSI; PhD/U-Pitt, Post-Doc/MDA https://www.linkedin.com/in/michael-gray-18447328
- - - - - -
BAVI MOA 5-11-16 Breast Cancer Res. article, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC” http://tinyurl.com/zxu882y
Lead author: Michael Gray; Senior author: Bruce Freimark; Co-author: Christopher C. W. Hughes(U-Cal/Irvine)
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”